{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:23:07Z","timestamp":1794248587903,"version":"4.9.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["1S10RR024523-01"],"award-info":[{"award-number":["1S10RR024523-01"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.isci.2026.117008","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:21:36Z","timestamp":1785856896000},"page":"117008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tunable universal OR-gated CAR T cells for AML"],"prefix":"10.1016","volume":"29","author":[{"given":"Menna Y.","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey Zhuoying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Loffredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongshuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelia","family":"Leemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela Guzm\u00e1n","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas W.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-889X","authenticated-orcid":false,"given":"Wilson W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117008_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"New England J. Med."},{"key":"10.1016\/j.isci.2026.117008_bib2","unstructured":"Acute Myeloid Leukemia \u2014 Cancer Stat Facts. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"10.1016\/j.isci.2026.117008_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100703","article-title":"Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia","volume":"52","author":"Long","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.isci.2026.117008_bib4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.117008_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117008_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12185-018-2412-8","article-title":"Hematopoietic stem cell transplantation for acute myeloid leukemia","volume":"107","author":"Takami","year":"2018","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.isci.2026.117008_bib7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: New drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.117008_bib8","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s12185-022-03370-4","article-title":"Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges","volume":"116","author":"Capria","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.isci.2026.117008_bib9","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.3390\/cancers14174166","article-title":"A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges","volume":"14","author":"Awada","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.117008_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.117008_bib11","first-page":"878","article-title":"Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed\/Refractory Large B-Cell Lymphoma","volume":"10","author":"King","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.isci.2026.117008_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117008_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117008_bib14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.isci.2026.117008_bib15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood-2021-147563","article-title":"Brexucabtagene Autoleucel for Relapsed\/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117008_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117008_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-019-0705-x","article-title":"Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia","volume":"12","author":"Zhao","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117008_bib18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117008_bib19","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117008_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MOH.0000000000000626","article-title":"Genetic Heterogeneity and Clonal Evolution in Acute Myeloid Leukemia","volume":"28","author":"Romer-Seibert","year":"2021","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.isci.2026.117008_bib21","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1073\/pnas.1902375116","article-title":"Heterogeneity in refractory acute myeloid leukemia","volume":"116","author":"Horibata","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117008_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1085978","article-title":"Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia","volume":"13","author":"Schorr","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117008_bib23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.117008_bib24","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering advanced logic and distributed computing in human CAR immune cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117008_bib25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41467-020-20785-x","article-title":"Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma","volume":"12","author":"Moghimi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117008_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1\u2013 and CTLA-4\u2013Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.117008_bib27","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117008_bib28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.117008_bib29","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117008_bib30","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1038\/s41467-020-17970-3","article-title":"Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function","volume":"11","author":"Salzer","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117008_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.copbio.2020.01.009","article-title":"All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy","volume":"65","author":"Lanitis","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.isci.2026.117008_bib32","doi-asserted-by":"crossref","first-page":"780399","DOI":"10.3389\/fimmu.2021.780399","article-title":"Implementing Logic Gates for Safer Immunotherapy of Cancer","volume":"12","author":"Savanur","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117008_bib33","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.117008_bib34","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117008_bib35","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117008_bib36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3324\/haematol.2022.281456","article-title":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia","volume":"108","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.117008_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117008_bib38","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.117008_bib39","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/cancers13133214","article-title":"CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin","volume":"13","author":"Molica","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.117008_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-020-00975-2","article-title":"Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia","volume":"13","author":"Cortes","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117008_bib41","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2019-127977","article-title":"Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33\/CD3 BiTE\u00ae (Bispecific T-Cell Engager) in Patients with Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML)","volume":"134","author":"Subklewe","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117008_bib42","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00262-023-03439-x","article-title":"CD33 BiTE\u00ae molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells","volume":"72","author":"Marcinek","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.isci.2026.117008_bib43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.117008_bib44","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s43018-023-00642-8","article-title":"A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo","volume":"4","author":"Giannakopoulou","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.isci.2026.117008_bib45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s13287-021-02420-8","article-title":"Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.isci.2026.117008_bib46","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2020006921","article-title":"CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy","volume":"137","author":"Willier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117008_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003882","article-title":"A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL","volume":"10","author":"Mehta","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117008_bib48","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001029","article-title":"Isolation of a Highly Purified HSC-enriched CD34+CD90+CD45RA\u2212 Cell Subset for Allogeneic Transplantation in the Nonhuman Primate Large-animal Model","volume":"6","author":"Radtke","year":"2020","journal-title":"Transplant. Direct"},{"key":"10.1016\/j.isci.2026.117008_bib49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117008_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799206","article-title":"Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of \u201cOn-Target, Off-Tumor Toxicity\u201d","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117008_bib51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117008_bib52","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.117008_bib53","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.isci.2026.117008_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117008_bib55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.117008_bib56","unstructured":"AbbVie & Scripps-based Calibr Moves Novel \u2018Switchable\u2019 CAR-T Technology to Phase I Clinical Trial. https:\/\/www.trialsitenews.com\/a\/abbvie-scripps-based-calibr-moves-novel-switchable-car-t-technology-to-phase-i-clinical-trial."},{"key":"10.1016\/j.isci.2026.117008_bib57","unstructured":"Scripps Research. Calibr reports promising results from first-in-human clinical trial of switchable CAR-T (CLBR001 + SWI019), a next-generation universal CAR-T platform designed to enhance the versatility and safety of cell therapies. https:\/\/www.scripps.edu\/news-and-events\/press-room\/2022\/20220921-calibr-cart.html."},{"key":"10.1016\/j.isci.2026.117008_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.996438","article-title":"Developments and challenges of FLT3 inhibitors in acute myeloid leukemia","volume":"12","author":"Ge","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117008_bib59","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/biomedicines12010208","article-title":"Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms\u2014A Systematic Review","volume":"12","author":"Collados-Ros","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2026.117008_bib60","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","article-title":"In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","volume":"32","author":"An","year":"2026","journal-title":"Nat. Med."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226023862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226023862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:59:01Z","timestamp":1794247141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226023862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2589004226023862"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117008","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tunable universal OR-gated CAR T cells for AML","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117008"}}